What is the average price of bhasma exports from India?

The average unit price for bhasma exports from India is $10.88 USD per unit, with prices ranging from $0.08 to $1452.78 depending on formulation, packaging, and order volume. The total market is valued at $414.6K across 720 shipments.

Which ports handle bhasma exports from India?

The primary ports for bhasma exports from India are RAXAUL (INRXLB) (13.6% of shipments), RAXAUL (10.6% of shipments), NHAVA SHEVA SEA (INNSA1) (6.7% of shipments), DELHI AIR CARGO ACC (INDEL4) (6.4% of shipments), COCHIN SEA (INCOK1) (6.1% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of bhasma?

India is one of the world's leading exporters of bhasma due to its large base of 76 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports bhasma to 34 countries, demonstrating 17% global market coverage.

What certifications do Indian bhasma exporters need?

Indian bhasma exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import bhasma from India?

There are 146 registered buyers importing bhasma from India, spread across 34 countries. The repeat buyer rate is 63.0%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top bhasma supplier from India?

AJANTA PHARMA LIMITED is the leading bhasma exporter from India with a market share of 17.8% and total export value of $73.6K across 27 shipments. The top 5 suppliers together control 56.3% of total export value.

Bhasma

India Pharmaceutical Trade Intelligence

$414.6K76 Suppliers34 CountriesHS 30049011

ExportsIndia → NEPAL35.1%India → UNITED ARAB13.5%

#1 Supplier: AJANTA PHARMA #1 Buyer: PLANET PHARMA

Bhasma Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Bhasma to the World

Q: Who are the top bhasma exporters from India?

The top bhasma exporters from India are: 1. AJANTA PHARMA LIMITED — $73.6K (17.8% market share); 2. SHREE DHOOTAPAPESHWAR LIMITED — $55.1K (13.3% market share); 3. PATANJALI AYURVED LIMITED — $37.8K (9.1% market share); 4. DABUR INDIA LIMITED — $33.8K (8.2% market share); 5. U SQUARE LIFESCIENCE PRIVATE LIMITED — $33.2K (8.0% market share). Together they account for 56.3% of India's total bhasma export value.

Q: What is the total export value of bhasma from India?

The total export value of bhasma from India is $414.6K USD, recorded across 720 shipment transactions from 76 active exporters to 34 destination countries. The average shipment value is $576.

Q: Which countries import bhasma from India?

India exports bhasma to 34 countries worldwide. The top importing countries are: NEPAL (35.1% share, $145.6K), UNITED ARAB EMIRATES (13.5% share, $55.8K), KYRGYZSTAN (10.2% share, $42.3K), DOMINICAN REPUBLIC (8.0% share, $33.2K), FRANCE (7.4% share, $30.8K). These five markets account for 74.2% of total export value.

Q: What is the HS code for bhasma exports from India?

The primary HS code for bhasma exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Between 2022 and 2026, India exported $414.6K worth of bhasma across 720 verified shipments to 34 countries — covering 17% of world markets in the Ayurvedic & Herbal Products segment. The largest destination is NEPAL (35.1%). AJANTA PHARMA LIMITED leads with a 17.8% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Bhasma export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Bhasma export data snapshot — $414.6K · 76 exporters · 34 countriesTransData Nexus · Indian Customs Data

Top Bhasma Exporters from India

76 active exporters · Ranked by export value

View all 76 →

Top Bhasma Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	AJANTA PHARMA LIMITED	$73.6K	27	3	17.8%
2	SHREE DHOOTAPAPESHWAR LIMITED

Top Countries Importing Bhasma from India

34 destination markets · Ranked by import value

All 34 countries →

Top Countries Importing Bhasma from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	NEPAL	$145.6K	35.1%
2	UNITED ARAB EMIRATES	$55.8K	13.5%
3	KYRGYZSTAN	$42.3K	10.2%
4	DOMINICAN REPUBLIC	$33.2K	8.0%
5	FRANCE	$30.8K	7.4%
6	NETHERLANDS	$26.9K	6.5%
7	UNITED KINGDOM	$16.7K	4.0%
8	SRI LANKA	$14.5K	3.5%
9	UNITED STATES	$12.3K	3.0%
10	SOMALIA	$6.5K	1.6%

NEPAL is India's largest bhasma export destination, absorbing 35.1% of total exports worth $145.6K. The top 5 importing countries — NEPAL, UNITED ARAB EMIRATES, KYRGYZSTAN, DOMINICAN REPUBLIC, FRANCE — together account for 74.2% of India's total bhasma export value. The remaining 29 destination countries collectively receive the other 25.8%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Bhasma

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for Bhasma products. This indicates that no Bhasma formulations have received FDA approval for marketing in the United States. Furthermore, the FDA has issued warnings regarding certain unapproved Ayurvedic products containing harmful levels of heavy metals, such as lead and mercury. In February 2026, the FDA highlighted the risks associated with these products, emphasizing potential health hazards like heavy metal poisoning. Consequently, Bhasma products intended for the U.S. market must undergo rigorous evaluation to ensure compliance with FDA standards, particularly concerning safety and labeling. Given the absence of approved ANDAs and the FDA's stringent stance on unapproved Ayurvedic products, Indian exporters face significant regulatory challenges when entering the U.S. market.

2EU & UK Regulatory Framework

In the European Union, Ayurvedic products like Bhasma are subject to the European Medicines Agency's (EMA) guidelines for traditional herbal medicinal products. To obtain marketing authorization, these products must demonstrate safety, quality, and efficacy. As of March 2026, there are no specific EMA approvals for Bhasma products. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) categorizes medicinal products to determine applicable regulations. The MHRA's categorization lists, updated in February 2026, do not specifically mention Bhasma, indicating that such products may require individual assessment for market entry. Compliance with Good Manufacturing Practice (GMP) standards is mandatory in both jurisdictions, ensuring product quality and safety.

3WHO Essential Medicines & Global Standards

Bhasma products are not included in the World Health Organization's (WHO) Model List of Essential Medicines as of the latest edition. Additionally, these products have not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, Bhasma formulations are primarily described in the Indian Pharmacopoeia (IP). They are not monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), or European Pharmacopoeia (EP), which may pose challenges for international standardization and acceptance.

4India Regulatory Classification

In India, Bhasma products are regulated under the Drugs and Cosmetics Act, 1940, and are classified as Ayurvedic medicines. They are not listed under Schedules H, H1, or X, which pertain to allopathic drugs requiring specific prescriptions. As of March 2026, the National Pharmaceutical Pricing Authority (NPPA) has not imposed ceiling prices on Bhasma products, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

5Patent & Exclusivity Status

Bhasma products, being traditional Ayurvedic formulations, are generally not subject to patent protection. This lack of exclusivity allows multiple manufacturers to produce and market these products, leading to a competitive market landscape. However, the absence of patent protection also means that manufacturers cannot leverage exclusivity to command premium pricing or market share.

6Recent Industry Developments

In August 2025, the Indian Ministry of AYUSH introduced new guidelines to enhance the quality control of Ayurvedic products, including Bhasma, aiming to standardize manufacturing processes and ensure product safety. In October 2025, the NPPA conducted a review of Ayurvedic product pricing but did not implement any price controls on Bhasma products, maintaining a market-driven pricing approach. In December 2025, the DGFT streamlined the export NOC process for Ayurvedic products, reducing processing times and facilitating international trade. In January 2026, the WHO released a report emphasizing the need for stringent heavy metal testing in traditional medicines, prompting Indian manufacturers to adopt more rigorous quality control measures. In March 2026, the EMA updated its guidelines for traditional herbal medicinal products, potentially impacting the regulatory pathway for Bhasma products seeking entry into the European market.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Bhasma

Retail & reference prices across 9 markets vs. India FOB export price of $10.88/unit

Global Price Benchmark for Bhasma across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	N/A	USD	Swarna Bhasma is not listed in the FDA's Orange Book, indicating it is not an FDA-approved drug.
United Kingdom	N/A	GBP	Swarna Bhasma is not listed in the NHS Drug Tariff, suggesting it is not a standard prescription item within the NHS.
Germany	N/A	EUR	Swarna Bhasma is not listed in the German Federal Institute for Drugs and Medical Devices (BfArM) database, indicating it is not a registered medicinal product in Germany.
Australia	N/A

Supply Chain Risk Assessment — Bhasma

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of traditional medicines like Bhasma, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese suppliers, underscoring a significant dependency on external sources for critical raw materials. This reliance exposes the supply chain to vulnerabilities, particularly during geopolitical tensions or global disruptions.

The COVID-19 pandemic highlighted these risks when disruptions in Chinese manufacturing led to shortages and price hikes for essential APIs and KSMs. In response, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic production of key pharmaceutical ingredients and reduce import dependence. Despite these efforts, the transition to self-sufficiency is ongoing, and the industry remains susceptible to external supply chain disturbances.

2Supplier Concentration & Single-Source Risk

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five exporters of Bhasma from India account for 56.3% of total exports, with AJANTA PHARMA LIMITED leading at a 17.8% share. This concentration indicates a moderate level of supplier dependency, which could pose risks if any of these key exporters face operational challenges.

Access Complete Bhasma Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 720 transactions across 34 markets.

Request Demo View Pricing

Frequently Asked Questions — Bhasma Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top bhasma exporters from India?

The leading bhasma exporters from India are AJANTA PHARMA LIMITED, SHREE DHOOTAPAPESHWAR LIMITED, PATANJALI AYURVED LIMITED, and 9 others. AJANTA PHARMA LIMITED leads with 17.8% market share ($73.6K). The top 5 suppliers together control 56.3% of total export value.

What is the total export value of bhasma from India?

The total export value of bhasma from India is $414.6K, recorded across 720 shipments from 76 active exporters to 34 countries. The average shipment value is $576.

Which countries import bhasma from India?

India exports bhasma to 34 countries. The top importing countries are NEPAL (35.1%), UNITED ARAB EMIRATES (13.5%), KYRGYZSTAN (10.2%), DOMINICAN REPUBLIC (8.0%), FRANCE (7.4%), which together account for 74.2% of total export value.

What is the HS code for bhasma exports from India?

The primary HS code for bhasma exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Bhasma

Bhasma

How India Exports Bhasma to the World

Top Bhasma Exporters from India

Top Countries Importing Bhasma from India

Quick Facts

Related Ayurvedic & Herbal Products

Related Analysis

Need Details?

Regulatory Landscape — Bhasma

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Bhasma

Supply Chain Risk Assessment — Bhasma

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Bhasma Trade Intelligence

Frequently Asked Questions — Bhasma Exports from India

Who are the top bhasma exporters from India?

What is the total export value of bhasma from India?

Which countries import bhasma from India?

What is the HS code for bhasma exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of bhasma exports from India?

Which ports handle bhasma exports from India?

Why is India a leading exporter of bhasma?

What certifications do Indian bhasma exporters need?

How many buyers import bhasma from India?

What is the market share of the top bhasma exporter from India?

Analysis Methodology